Lars Lütjohan Jensen, attorney-at-law (Chairman).
Board Member (since 2016).
Extensive experience within Life Science e.g. cross-border M&A, capital markets, securities law, venture capital investments and ECM transactions regarding both publicly listed and unlisted companies. Further, he has substantial experience with IPOs and fundraising in both publicly listed and unlisted companies and has within M&A provided advise in numerous large and complicated M&A transactions, including auction processes.
Attorney-at-law(L), LL.B, Partner, Mazanti-Andersen Korsø Jensen. Admittet to the High Court (2015). BoD: Birn Foundation, Vald.Birn Holding, Abrahamsons Memorial Trust, B93 Football Club, Pantebrevselskabet CPH /S/S, Mazanti-Andersen Korsø Jensen, Ejendomsselskabet Hjallse 2014 A/S, Barir Holdingg ApS, 93 Invest Aps.
Has provided legal services to ParaTech since 2004.
Christian Kapel, professor, PhD
Founder and CEO of ParaTech (since 2004).
10 years of experience with GMP manufacture of API for biological drugs, preclinical and clinical research within helminth therapy (TSO). 20 years of research experience within host-parasite biology, molecular diagnostics and immune stimulation (Royal Veterinary and Agricultural University DK, US Dept. of Agriculture, University of Copenhagen). Has served in the BoD of ParaTest Aps (chairman 2004-15) and ParaTech A/S (2004-).
Professor and head of the Host & Parasite research group (Organismal Biology, Faculty of Science, UC), member of Academic Council (University of Copenhagen). Advisory board of Danish Centre for Experimental Parasitology (1995-2000), Head of Studies at Faculty of Science (2003-2013). Advisory expert for the EU Commission, FAO, OIE, OECD and WHO. Over 180 scientific publications (H-index 31, +3000 citations) and has lead several national and international research projects within e.g. host-parasite biology, parasite epidemiology, clinical parasitology and molecular diagnostics. Has supervised 31 BSc students, 40 MSc students, 11 PhD students, 3 post docs. Has been awarded the Crown Prince Frederik's Award, the OECD Research and Mobility Award, and the Teacher of the Year Award (UC).
Hanne Schultz Kapel, MSc
CCO of ParaTech (since 2016)
Extensive business experience within pharma commercial roles and management. 14 years at executive level with P&L responsibility at Roche. Over 20 years in pharma marketing, sales, communication, market access, medical and medicinal information. Leadership of international projects with significant results. Therapeutic expertise: Oncology, hematology, immunology, rheumatology, pulmonology, diabetes, obesity, cardiovascular- and metabolic diseases, autoimmune diseases, virology, CNS, transplantation, anaemia, dermatology, gastroenterology, infection, allergy, osteoporosis. Since 2006 experience with biologic products (monoclonal antibodies).
Christian Karsten Hansen, MSc, PhD, MBA
Served as senior scientist and director of intellectual property management at Novo Nordisk 1992–1999, and was a member of Enzyme Research Management. Co-founded Profound Pharma in 1999 and served as co-CEO until its acquisition by Maxygen in 2000. In 2001, he co-founded the investment firm Nordic Biotech Advisors (renamed NB Capital). Also in 2001, he founded C Hansen Invest. Co-founded and/or been a board member of numerous privately held and listed biotechnology companies including Osteologix, Nuevolution, Curalogic, Forward Pharma, Rose Pharma, Poalis, Aditech Pharma, and Veloxis Pharmaceuticals. Educated as MSc chemical engineering from the Technical University of Denmark, PhD work in molecular biology and biochemistry Pasteur Institute, France and the University of Salamanca, Spain. MBA from the Edinburgh Business School, Scotland. Has filed numerous patent applications in the fields of genetics of bacteria, cellulases and other enzymes, osteoporosis, and protein engineering and uses of biopharmaceuticals.